Antithrombotic therapy for chronic ischemic heart disease: how to balance risk and benefit in different categories of patients?

The review focuses on current guidelines for the use of medications that affect hemostasis in the treatment of patients with chronic ischemic heart disease (IHD). The review shows the important impact of negative outcomes of IHD on mortality from cardiovascular system diseases in the Russian Federation. The results of the most significant randomised clinical trials, which assessed the efficacy and safety of various antithrombotic therapy options in patients with various clinical manifestations of IHD, as well as methodological methods for individual assessment of ischemic and hemorrhagic risks, were discussed. Theoretically, the use of anticoagulants in combination with antithrombocytic drugs to reduce the risk of atherothrombotic complications in the phase of the stable course of the IHD is justified. The results of the COMPASS study, which proved the positive effect oflow-dose addition of rivaroxaban to acetylsalicylic acid on the risk of cardiovascular events, cardiovascular death and death from all causes in patients with chronic IHD with maintained sinus rhythm, are reviewed in detail. Discussions were held on how to determine the optimal duration of double antithrombocytic therapy in patients with IHD after percutaneous coronary intervention (PCI), taking into account individual values of ischemic and hemorrhagic risks. Long-term antithrombotic therapy schemes for patients with chronic IHD and atrial fibrillation (AF) that have not been exposed to PCI are presented, as well as current recommendations on how to choose the best antithrombotic therapy scheme for patients with IHD that have been exposed to PCI depending on the risk of stent thrombosis and the risk of bleeding. It has been substantiated that active differentiated antithrombotic therapy should be widely used in everyday practice, which, provided that ischemic and hemorrhagic risks are adequately assessed, creates a real prospect of reducing mortality from IHD and circulatory system diseases in general.

1. Shalnova S.A., Oganov R.G. Five year dynamics of main clinical symptoms in patients with ischemic heart disease in russia in comparison with other countries (the clarify registry). Kardiologiia. 2017;57(1):17-22. (In Russ.) Available at: https://elibrary.ru/item.asp?id=28298453.

2. Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Bretano C. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2019;41(3):407-477. doi: 10.1093/eurheartj/ehz425.

3. Collet J.-Ph., Thiele H., Barbato E., Barthelemy O., Bauersachs O., Bhatt D.L. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2020:ehaa575. doi: 10.1093/eurheartj/ehaa575.

4. Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;39(2):119-177. doi: 10.1093/eurheartj/ehx393.

5. Bonaca M.P., Bhatt D.L., Cohen M., Sterg Ph.B., Storey F.M., Jensen E.C. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-1800. doi: 10.1056/NEJMoa1500857.

6. Bonaca M.P., Bhatt D.L., Cohen M., Sterg Ph.B., Storey F.M., Jensen E.C. et al. Ischaemic risk and efficacy of ticagrelor in relation to time prior from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016;37(14):1133-1142. doi: 10.1093/eurheartj/ehv531.

7. Bhatt D.L., Fox K.A., Hacke W., Berger B.P., Black R.H., Boden W.E. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrom-botic events. N Engl J Med. 2006;354(16):1706-1717. doi: 10.1056/NEJMoa060989.

8. Bhatt D.L., Fox K.A., Hacke W., Berger B.P., Black R.H., Boden W.E. et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19):1982-1988. doi: 10.1016/j.jacc.2007.03.025.

9. Morrow D.A., Braunwald E., Bonaca M.P., Ameriso S.F., Dalby A.J., Fish M.P. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404-1413. doi: 10.1056/NEJMoa1200933.

10. Mega J.L., Braunwald E., Wiviott S.D., Winiott S.D., Bassand J-P., Bhatt D.L. et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012;366(1):9-19. doi: 10.1056/NEJMoa1112277.

11. Eikelboom J.W., Connolly S.J., Bosch J., Dagenais G.R., Hart R.G., Shestakovska O. et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319-1330. doi: 10.1056/NEJMoa1709118.

12. Connolly S.J., Eikelboom J.W., Bosch J., Dagenais G., Dyal L., Lanas F. et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205-218. doi: 10.1016/S0140-6736(17)32458-3.

13. Bosch J., Eikelboom J.W., Connolly S.J., Bruns N.C., Lanius V., Yuan F. et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol. 2017;33(8):1027-1035. doi: 10.1016/j.cjca.2017.06.001.

14. Neumann F.-J., Sousa-Uva M., Ahliston A., Alfonso F., Banning A.P., Benedetto U. et al. 2018 ESC/EACT Guidelines on myocardial revascularization. Eur Heart J. 2018;40(2):87-165. doi: 10.1093/eurheartj/ehy394.

15. Valgimigli M., Bueno H., Byrne R.A., Collet J-Ph., Costa F., Jeppsson A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2017;39(3):213-260. doi: 10.1093/eurheartj/ehx419.

16. Costa F., Van Klaveren D., James S., Heg D., Raber L., Feres F. et al. Derivation and validation of predicting bleeding complication in patients undergoing and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025-1034. doi: 10.1016/S0140-6736(17)30397-5.

17. Yeh R.W., Secemsky E.A., Kereiakes D.J., Normand S-L.T., Gershlick A.H., Cohen D.J. et al. DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315(16):1735-1749. doi: 10.1001/jama.2016.3775.

18. Kereiakes D.J., Yeh R.W., Massaro J.M., Cutlip D.E., Steg P.G., Wiviott S.D. et al. DAPT score utility for risk prediction in patients with or without previous myocardial infarction. JACC. 2016;67(21):2492-2502. doi: 10.1016/j.jacc.2016.03.485.

19. Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blondstron-Linkvist C. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020:ehaa612. doi: 10.1093/eurheartj/ehaa612.

20. Lamberts M., Olesen J.B., Ruwald M.H., Hansen C.M., Karasoy D., Kristensen S.L. et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126(10):1185-1193. doi: 10.1161/CIRCULATIONAHA.112.114967.

21. D'Ascenzo F., Taha S., Moretti C., Omede P., Grossomarra W., Persson J. et al. Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2015;115(9):1185-1193. doi: 10.1016/j.amj-card.2015.02.003.

22. Bavishi C., Koulova A., Bangalore S., Savant A., Chatterjee S., Ather S. et al. Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: a metaanalysis of observational studies. Catheter Cardiovasc Interv. 2016;88(1):E12-E22. doi: 10.1002/ccd.26234.

23. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B. et al. 2016 ESC Guidelines for the management of atrial fibrillati on developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210.

24. Dewilde W.J., Oirbans T., Verheugt F.W., Kelder J.C., de Smet B.J.G., Herrman J-P. et al. Use of clopido-grel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary interventi on: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107-1115. doi: 0.1016/S0140-6736(12)62177-1.

25. Chhatriwalla A.K., Amin A.P., Kennedy K.F., House J.A., Cohen D.J., Rao S.V. et al. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA. 2013;309(10):1022-1029. doi: 10.1001/jama.2013.1556.

26. Rubboli A., Schlitt A., Kiviniemi T., Biancari F., Karjalainen P.P., Valencia J. et al. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry. Clin Cardiol. 2014;37(6):357-364. doi: 10.1002/clc.22254.

27. Gibson C.M., Mehran R., Bode C., Halperin J., Verheugt F.W., Wildgoose P. et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423-2434. doi: 10.1056/NEJMoa1611594.

28. Cannon C.P., Bhatt D.L., Oldgren J., Lip G.Y.H., Ellis S.G., Kimura T. et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513-1524. doi: 10.1056/NEJMoa1708454.

29. Lopes R.D., Heizer G., Aronson R., Vora A.N., Massaro T., Mehran R. et al. AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509-1524. doi: 10.1056/NEJMoa1817083.

30. Golwala H.B., Cannon C.P., Steg P.G., Doros G., Qamar A., Ellis S.G. et al. Safety and efficacy of dual vs. triple antithrombotic therapy inpatients with atrial fibrillation following percutaneous coronary intervention: a systematic review and metaanalysis of randomized clinical trials. Eur Heart J. 2018;39(19):1726-1735. doi: 10.1093/eurheartj/ehy162.